Kenneth Janzon
Directeur Technique/Scientifique/R&D chez Nordvacc Läkemedel AB
Fortune : 439 236 $ au 30/04/2024
Postes actifs de Kenneth Janzon
Sociétés | Poste | Début | Fin |
---|---|---|---|
Nordvacc Läkemedel AB
Nordvacc Läkemedel AB Medical DistributorsDistribution Services Part of Intervacc AB, Nordvacc Läkemedel AB is a veterinary pharmaceutical company based in Hägersten, SE. Nordvacc Läkemedel AB was acquired by Sorkaruga AB on March 25, 2014. The Swedish company specializes in the distribution and marketing of veterinary vaccines and medicines for the care and treatment of both companion and farm animals. The company's flagship product, infucal® vet, is a solution for calving paralysis and is vital for the survival of cattle. The product contains calcium, magnesium, a source of phosphorus in the form of sodium hypophosphite, and glucose, which counteracts hypomagnesemia and is used to treat other conditions with hypocalcemia in animals. The CEO of the company is Rune Bergman. | Directeur Technique/Scientifique/R&D | - | - |
Historique de carrière de Kenneth Janzon
Anciens postes connus de Kenneth Janzon
Sociétés | Poste | Début | Fin |
---|---|---|---|
INTERVACC AB | Directeur/Membre du Conseil | 01/01/2001 | 14/06/2018 |
Fondateur | 01/01/2001 | 14/06/2018 | |
Independent Dir/Board Member | 01/01/2001 | - |
Statistiques
Internationale
Suède | 3 |
Opérationnelle
Director/Board Member | 1 |
Founder | 1 |
Independent Dir/Board Member | 1 |
Sectorielle
Health Technology | 2 |
Distribution Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
INTERVACC AB | Health Technology |
Entreprise privées | 1 |
---|---|
Nordvacc Läkemedel AB
Nordvacc Läkemedel AB Medical DistributorsDistribution Services Part of Intervacc AB, Nordvacc Läkemedel AB is a veterinary pharmaceutical company based in Hägersten, SE. Nordvacc Läkemedel AB was acquired by Sorkaruga AB on March 25, 2014. The Swedish company specializes in the distribution and marketing of veterinary vaccines and medicines for the care and treatment of both companion and farm animals. The company's flagship product, infucal® vet, is a solution for calving paralysis and is vital for the survival of cattle. The product contains calcium, magnesium, a source of phosphorus in the form of sodium hypophosphite, and glucose, which counteracts hypomagnesemia and is used to treat other conditions with hypocalcemia in animals. The CEO of the company is Rune Bergman. | Distribution Services |
- Bourse
- Insiders
- Kenneth Janzon
- Expérience